News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
715,520 Results
Type
Article (42344)
Company Profile (294)
Press Release (672882)
Section
Business (210375)
Career Advice (2091)
Deals (36626)
Drug Delivery (106)
Drug Development (83019)
Employer Resources (175)
FDA (16548)
Job Trends (15395)
News (355909)
Policy (33880)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2590)
Accelerated approval (2)
Adcomms (21)
Allergies (84)
Alliances (51366)
ALS (85)
Alzheimer's disease (1364)
Antibody-drug conjugate (ADC) (115)
Approvals (16549)
Artificial intelligence (242)
Autoimmune disease (15)
Automation (14)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (19)
Biosimilars (107)
Biotechnology (188)
Bladder cancer (56)
Brain cancer (26)
Breast cancer (248)
Cancer (2000)
Cardiovascular disease (163)
Career advice (1749)
Career pathing (30)
CAR-T (141)
Cell therapy (398)
Cervical cancer (17)
Clinical research (67214)
Collaboration (780)
Compensation (451)
Complete response letters (25)
COVID-19 (2652)
CRISPR (40)
C-suite (209)
Cystic fibrosis (101)
Data (1930)
Decentralized trials (2)
Denatured (26)
Depression (39)
Diabetes (251)
Diagnostics (6414)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (113)
Drug pricing (107)
Drug shortages (28)
Duchenne muscular dystrophy (85)
Earnings (87834)
Editorial (33)
Employer branding (21)
Employer resources (149)
Events (114455)
Executive appointments (642)
FDA (17662)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (693)
Gene editing (101)
Generative AI (20)
Gene therapy (289)
GLP-1 (717)
Government (4499)
Grass and pollen (4)
Guidances (48)
Healthcare (18986)
Huntington's disease (23)
IgA nephropathy (22)
Immunology and inflammation (112)
Indications (27)
Infectious disease (2781)
Inflammatory bowel disease (135)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (85)
Interviews (322)
IPO (16762)
IRA (47)
Job creations (4055)
Job search strategy (1492)
Kidney cancer (9)
Labor market (34)
Layoffs (471)
Leadership (16)
Legal (8367)
Liver cancer (71)
Lung cancer (290)
Lymphoma (131)
Machine learning (2)
Management (59)
Manufacturing (277)
MASH (62)
Medical device (13400)
Medtech (13405)
Mergers & acquisitions (20325)
Metabolic disorders (650)
Multiple sclerosis (68)
NASH (17)
Neurodegenerative disease (80)
Neuropsychiatric disorders (26)
Neuroscience (1844)
NextGen: Class of 2025 (6637)
Non-profit (4524)
Northern California (2403)
Now hiring (37)
Obesity (353)
Opinion (226)
Ovarian cancer (72)
Pain (85)
Pancreatic cancer (77)
Parkinson's disease (131)
Partnered (20)
Patents (206)
Patient recruitment (94)
Peanut (49)
People (59030)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20841)
Phase II (29575)
Phase III (22170)
Pipeline (983)
Podcasts (74)
Policy (120)
Postmarket research (2654)
Preclinical (8833)
Press Release (68)
Prostate cancer (93)
Psychedelics (31)
Radiopharmaceuticals (249)
Rare diseases (369)
Real estate (6251)
Recruiting (67)
Regulatory (22981)
Reports (46)
Research institute (2365)
Resumes & cover letters (358)
Rett syndrome (3)
RNA editing (3)
RSV (37)
Schizophrenia (70)
Series A (123)
Series B (78)
Service/supplier (12)
Sickle cell disease (52)
Southern California (2077)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (29)
Startups (3721)
State (2)
Stomach cancer (13)
Supply chain (60)
The Weekly (45)
United States (21116)
Vaccines (673)
Venture capitalists (37)
Webinars (12)
Weight loss (241)
Women's health (33)
Worklife (15)
Date
Today (93)
Last 7 days (613)
Last 30 days (2527)
Last 365 days (34081)
2025 (7850)
2024 (35770)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33138)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (780)
Alabama (49)
Alaska (7)
Arizona (230)
Arkansas (14)
Asia (40575)
Australia (6498)
California (5487)
Canada (1868)
China (480)
Colorado (247)
Connecticut (257)
Delaware (126)
Europe (86493)
Florida (812)
Georgia (190)
Idaho (57)
Illinois (502)
India (24)
Indiana (298)
Iowa (9)
Japan (144)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (833)
Massachusetts (4161)
Michigan (210)
Minnesota (368)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1568)
New Mexico (29)
New York (1571)
North Carolina (931)
North Dakota (7)
Northern California (2403)
Ohio (190)
Oklahoma (14)
Oregon (38)
Pennsylvania (1251)
Puerto Rico (9)
Rhode Island (26)
South America (1160)
South Carolina (18)
South Dakota (1)
Southern California (2077)
Tennessee (92)
Texas (822)
Utah (165)
Virginia (135)
Washington D.C. (57)
Washington State (514)
West Virginia (3)
Wisconsin (51)
715,520 Results for "biocryst pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
February 12, 2025
·
5 min read
Press Releases
BioCryst to Present at Upcoming March 2025 Investor Conferences
February 20, 2025
·
1 min read
Bio NC
BioCryst to Present at Upcoming May 2024 Investor Conferences
BioCryst Pharmaceuticals, Inc. announced that the company will present at the following conferences.
May 7, 2024
·
1 min read
Bio NC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2024
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 74,875 shares, and restricted stock units covering an aggregate of 39,050 shares, of BioCryst common stock.
June 4, 2024
·
1 min read
Press Releases
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
February 10, 2025
·
1 min read
Press Releases
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2025
March 7, 2025
·
1 min read
Bio NC
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 03, 2024
BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 79,575 shares, and restricted stock units covering an aggregate of 42,400 shares, of BioCryst common stock.
May 3, 2024
·
1 min read
Press Releases
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
February 25, 2025
·
20 min read
Business
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
BioCryst Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 6, 2024
·
14 min read
Business
BioCryst to Report First Quarter 2024 Financial Results on May 6
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6, 2024.
April 22, 2024
·
1 min read
1 of 71,552
Next
